Publicacións nas que colabora con Miguel Ángel Sanz Alonso (8)

2011

  1. Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia

    Haematologica, Vol. 96, Núm. 10, pp. 1448-1456

  2. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q

    Leukemia, Vol. 25, Núm. 1, pp. 110-120

2010

  1. Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy

    Haematologica, Vol. 95, Núm. 3, pp. 424-431

2009

  1. C005 Prognostic impact of the proportion of aberrant metaphases in patients with a primary myelodysplastic syndrome

    Leukemia Research, Vol. 33, Núm. SUPPL. 1

2007

  1. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia

    European Journal of Haematology, Vol. 78, Núm. 2, pp. 102-110

2006

  1. Significado pronóstico de los subtipos inmunológicos de la leucemia aguda linfoblástica T del adulto. Estudio de 81 pacientes

    Medicina Clinica, Vol. 126, Núm. 2, pp. 41-46

2005

  1. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial

    Haematologica, Vol. 90, Núm. 10, pp. 1346-1356

2002

  1. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial

    Haematologica, Vol. 87, Núm. 2, pp. 154-166